Q3 FY2026 · ended Sep 27, 2026 · Revenue $25.40B, +5.9% YoY · Filed Oct 21, 2026
Johnson & Johnson (JNJ) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 27, 2026, it reported revenue of $25.4 billion and net income of $210.0 million. Free cash flow was $6.4 billion. As of Sep 27, 2026 it held $17.2 billion in cash and investments and $44.7 billion in total debt.
Revenue
$25.40B
+5.9% vs year-ago quarter
Net income
$210.00M
-95.9% vs year-ago quarter
Operating cash flow
$7.72B
-15.8% vs year-ago quarter
Free cash flow
$6.36B
-20.6% vs year-ago quarter
EPS
$0.09
-95.8% vs year-ago quarter
Dividend per share
$1.34
+3.1% vs year-ago quarter
Shares outstanding
2.41B
-0.1% vs year-ago quarter
Net cash
$-27.42B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 27, 2026 |
Q2 FY2026 Jun 28, 2026 |
Q1 FY2026 Mar 29, 2026 |
Q4 FY2025 Dec 28, 2025 |
Q3 FY2025 Sep 28, 2025 |
|---|---|---|---|---|---|
| Revenue | $25.4B | $25.3B | $24.1B | $24.6B | $24.0B |
| Net income | $210.0M | $5.5B | $5.2B | $5.1B | $5.2B |
| Diluted EPS | $0.09 | $2.27 | $2.14 | $2.09 | $2.12 |
| Operating cash flow | $7.7B | $8.6B | $2.5B | $7.3B | $9.2B |
| Free cash flow | $6.4B | $7.3B | $1.5B | $5.5B | $8.0B |
| Total assets | $197.4B | $201.1B | $200.9B | $199.2B | $192.8B |
| Total liabilities | $115.9B | $116.1B | $119.7B | $117.7B | $113.5B |
| Stockholders' equity | $81.5B | $85.0B | $81.2B | — | $79.3B |
| Cash and investments | $17.2B | $20.8B | $22.1B | $20.1B | $18.6B |
| Total debt | $44.7B | $49.0B | $55.0B | $51.3B | $45.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 21, 2026 | Sep 27, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2026 | Jul 27, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 28, 2026 |
All 1000 Johnson & Johnson SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.